Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Merck's New Pricing Pledge Shows Style Over Substance

A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV space overall is shrinking. Another set of 10% reductions come on small-sellers that are now generic. 

Pricing Debate Pricing Strategies Policy

FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models

In unveiling the agency’s Biosimilar Action Plan, FDA's Gottlieb continued his pattern of provocative remarks by criticizing brand company practices and payment models that impede biosimilar competition and could ultimately undermine innovation. He also called for more action by the Federal Trade Commission and downplayed the impact interchangeability could have on biosimilar uptake. 


Biosimilars Biologics Business Strategies

Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD

Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every four weeks. But while AMD patients would enjoy fewer sharp pokes in the eye, about 15% may experience inflammation – at least until a new formulation is available.

Clinical Trials Ophthalmic Comparative Effectiveness

Pharma's 2018 Deal-Making Story, So Far

Pharma has been busy making deals this year, while the political winds of change swirl overhead, as our infographic shows. Companies both big and small have been merging to carve out therapeutic niches, return value to shareholders, and position themselves for the next wave of innovation and change.

Commercial Deals M & A
Advertisement


 Recent Tweets from Scrip


Pharma Asset Insights

Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene therapies and antisense oligonucleotides demand that all health care stakeholders make efforts to move into the next generation of patient care and centricity.

Pharma Asset Insights provides a compilation of insights and data-driven analysis.

Read now and discover more

BLH Launch Excellence Survey

Pharma Intelligence in partnership with Blue Latitude Health is undertaking a survey to gather insight on the drivers, barriers, and trends of Launch Excellence in modern healthcare environment. Take this 5-10 minute survey and help shape the future of launch excellence. To show our appreciation for your time, each respondent to complete the survey will be entered in a draw to win one of four $100 Amazon gift cards.

Take the Survey Now

 

Commercial Explore this Topic

Set Alert for Commercial

Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb

Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.

Commercial Dermatology Deals

MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone

MaxCyte's first next-generation chimeric antigen receptor MCY-M11 will be studied in solid tumors.

Analysis Clinical Trials Business Strategies

J&J’s Symtuza Approved, But Commercial Outlook Uncertain

The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.

Approvals Infectious Diseases

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.

Sales & Earnings Manufacturing

Profile: Lupin CFO Swaminathan, The ‘Constant Learner'

CFOs are known for talking about their top and bottom lines, but not so much about what makes them tick. Here we give you a peek into the life story of Lupin CFO Ramesh Swaminathan, who shares with Scrip why he made the shift from Henkel in Germany to the Indian firm, M&A learnings, admiration for peer Sun Pharma and his own career ambitions.

 

Commercial Companies

Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market

Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.

Japan Commercial

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.

Sales & Earnings Pricing Debate

Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule

With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.

Financing Business Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price

Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.

Pricing Debate Pharmacy Benefit Management Medicare

Korea Eyes New Consortium To Support Innovation, Nurture Biotech Hubs

South Korea moves to support open innovation in the pharma and biotech industries, and to raise global competitiveness of biotech clusters in the country, in an effort to catch up with major overseas bio hubs such as the Boston Biotech Cluster.

South Korea Innovation

Siga Ready For Next Phase, New Cash With Smallpox Drug Approval

Siga is entitled to a $41m “hold back” payment under its contract with the Biomedical Advanced Research and Development Authority and potentially a $50m payment related to the US FDA's extended shelf-life determination for stockpiled Tpoxx; company also picks up first priority review voucher awarded for a medical countermeasure, which it likely will monetize.


Approvals Animal Testing

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

China India

Research & Development Explore this Topic

Set Alert for Research & Development

Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint

As Roche keeps building its catalog of positive Tecentriq results, its Phase III IMpower132 study meets PFS endpoint in NSCLC, with OS data coming later.

Clinical Trials ImmunoOncology Research & Development

Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Takeda and partner Ovid are planning new trials in rare pediatric indications for their first-in-class epilepsy drug, including in the increasingly competitive area of Dravet syndrome.

Clinical Trials Research & Development

Mersana's ADC Technology Faces A Setback With Partial Clinical Trial Hold

A patient death in a Phase I dose-escalation study of XMT-1522 in patients with HER2-expressing tumors rattled investors, but CEO Protopapas said it is not clear what the cause of death was in the very sick patient and that Mersana is working closely with the FDA.

Clinical Trials Research & Development

Bone Therapeutics: Helping Bone Regenerate, And To Knit Together

Executive Interview: A raft of clinical trial results are expected in the second half of 2018 for Bone Therapeutics' regenerative cell therapy approach to hip osteonecrosis and delayed-union fractures.

 

Clinical Trials Regenerative Medicine
UsernamePublicRestriction

Register

Advertisement